coreNASH: Multi‐stakeholder Consensus on Core Outcomes for Decision Making About Nonalcoholic Steatohepatitis Treatment

Elizabeth Clearfield, Veronica Miller, Joseph Nadglowski, Katherine Barradas, Jennifer Al Naber, Arun J. Sanyal, Brent A. Neuschwander‐Tetri, Donna A. Messner, the coreNASH Panel – 11 February 2021 – The increasing prevalence and burden of nonalcoholic steatohepatitis (NASH) has spurred the development of new treatments and a need to consider outcomes used for NASH treatment decision making. Development of a NASH core outcome set (COS) can help prioritize outcomes of highest importance by incorporating the perspectives from a variety of decision makers.

A Machine Learning Approach Enables Quantitative Measurement of Liver Histology and Disease Monitoring in NASH

Amaro Taylor‐Weiner, Harsha Pokkalla, Ling Han, Catherine Jia, Ryan Huss, Chuhan Chung, Hunter Elliott, Benjamin Glass, Kishalve Pethia, Oscar Carrasco‐Zevallos, Chinmay Shukla, Urmila Khettry, Robert Najarian, Ross Taliano, G. Mani Subramanian, Robert P. Myers, Ilan Wapinski, Aditya Khosla, Murray Resnick, Michael C. Montalto, Quentin M. Anstee, Vincent Wai‐Sun Wong, Michael Trauner, Eric J. Lawitz, Stephen A. Harrison, Takeshi Okanoue, Manuel Romero‐Gomez, Zachary Goodman, Rohit Loomba, Andrew H. Beck, Zobair M. Younossi – 10 February 2021

Subscribe to